IMIPRAMINE
A dibenzapine analogue of pheno thiazine is selectively beneficial to depressed but not agitated psychotics. In depressed patients little acute effects are produced, except sedation. After 2-3 weeks of continuous treatment the mood is gradually elevated, patients become more communicative and start taking more interest in self and surroundings. It is not euphorient but only anti depressant.Anxiety depression syndrome, nocturnal enuresis, narcolepsy.
25 mg-50 mg, 3 times a day gradually increased every week till under control. Max. 200 mg/day. Maint. minimum possible dosage. Therapy for atleast 1-3 weeks. Nocturnal enuresis: upto 12 yrs. 25 mg. Over 12 yrs. 50 mg bedtime.
heart block, narrow angle glaucoma, severe liver disease, acute recovery period after M.I. concomitant therapy with MAO inhibitors or within 14 days of discontinuing them.Hypersensitivity.
In Cardiovascular disease may induce postural hypotension. Epilepsy, hypertension, hyperthyroidism, glaucoma, urinary retention, renal or hepatic impairment. May potentiate actions of C.N.S. depressants like alcohol, barbiturates & tranquillisers. Paediatrics: Not recommended under 6 years. Reduce dose in older children. Pregnancy: Safety not established. Lactation: Drug passes in to breast milk. Elderly: Reduced dose may be necessary.
Dry mouth, constipation, urinary retention, blurred vision, changes in accomodation, palpitations, tachycardia, drowsiness, insomnia, nervousness, tremor, orthostatic hypotension, dizziness, sweating, weakness, fatigue, ataxia, epiletiform seizures, occasional extrapyramidal symptoms, gastric irritation. Weight loss or gain. Allergic skin reactions, jaundice, blood disorders, conduction defects, cardiac arrhythmias, changes in libido, impotence, gynaecomastia, galactorrhoea, blood sugar changes,
Severe hypertension with adrenaline, noradrenaline and methylphenidate. Reverses hypotension effects of guanethidine, betanidine and bretylium. Interferes with antihypertensive action of methyldopa and conidine. Major tranquillizers inhibit metabolism, oral contraceptive reduce bioavailability, barbiturates reduce plasma levels.
